LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Lista de Ações・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Fechado

SetorSaúde

33.29 -3.2

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

32.52

Máximo

34.36

Indicadores-chave
By Trading Economics
Rendimento	-14M -81M
Vendas	75K 75K
EPS	-1.22
Margem de lucro	-108,422.667
Funcionários	198
EBITDA	-7.8M -81M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+64.58% upside

Dividendos
By Dow Jones
Próximos Ganhos	13 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	956M 2.6B
Abertura anterior	36.49
Fecho anterior	33.29

Sentimento de Notícias

By Acuity

50%

166 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

18.91 / 20.63 Suporte e Resistência

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de mai. de 2026, 23:58 UTC

Ganhos

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 de mai. de 2026, 22:57 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 de mai. de 2026, 23:52 UTC

Ganhos

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 de mai. de 2026, 23:11 UTC

Ganhos

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 de mai. de 2026, 23:06 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 de mai. de 2026, 23:05 UTC

Ganhos

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 de mai. de 2026, 23:04 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 de mai. de 2026, 23:02 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 de mai. de 2026, 23:00 UTC

Conversa de Mercado

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 de mai. de 2026, 22:42 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 de mai. de 2026, 22:33 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 de mai. de 2026, 22:32 UTC

Ganhos

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie: 68% of FY Income From International >MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 de mai. de 2026, 22:29 UTC

Ganhos

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 de mai. de 2026, 22:26 UTC

Ganhos

Macquarie to End Share Buyback Extended in November>MQG.AU

7 de mai. de 2026, 22:25 UTC

Ganhos

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

64.58% parte superior

Previsão para 12 meses

Média 56.6 USD 64.58%

Máximo 90 USD

Mínimo 34 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

166 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.